Srdx qtr date5/11/2023 ![]() The Company expects fiscal 2021 diluted GAAP EPS to range from a loss per share of $(0.05) to earnings per share of $0.20. Surmodics expects fiscal year 2021 revenue to range from $101 million to $105 million. Capital expenditures totaled $0.7 million for the second quarter of fiscal 2021. Surmodics reported $16.0 million of cash provided by operating activities in the second quarter of fiscal 2021. ![]() On a non-GAAP basis, earnings per share in the second quarter of fiscal 2021 was $0.62, compared to $0.04 in the same prior-year quarter.Īs of March 31, 2021, Surmodics reported cash and investments totaling $70.0 million and no debt. In Vitro Diagnostics revenue was $7.1 million for the second quarter of fiscal 2021, compared to $6.5 million in the same prior-year quarter, an increase of 9%.ĭiluted GAAP earnings per share in the second quarter of fiscal 2021 was $0.58, compared to $0.11 in the year-ago period. This compares to $1.5 million in revenue recognized in the prior-year quarter. Medical Device revenue was $27.9 million for the second quarter of fiscal 2021, compared to $16.3 million for the year-ago period, an increase of 71%, and includes $12.5 million from our SurVeil DCB agreement with Abbott, of which $10.8 million was recognized on the $15 million milestone payment associated with the successful completion of the TRANSCEND clinical report. Total revenue for the second quarter of fiscal 2021 was $35.0 million, compared to $22.8 million in the prior-year period. Second Quarter Fiscal 2021 Financial Results This ongoing feedback validates our belief that our unique Sublime platform has the potential to improve patient outcomes and patient satisfaction while reducing healthcare costs.” 014 RX PTA Dilatation Catheter and Sublime Radial Access Guide Sheath. “In addition, we have received valuable initial feedback from physicians who have participated in our clinical product evaluations of both our Sublime. “We are pleased with our second quarter results which exceeded expectations, with record revenue performance in our In Vitro Diagnostics business and a return to growth in our Medical Device coatings royalty revenue,” said Gary Maharaj, President and CEO of Surmodics, Inc. Recognized $10.8 million in license fee revenue upon receipt of $15 million milestone payment under the SurVeil™ Development and Distribution Agreement with Abbott.Successful first patient uses of two Sublime™ radial access platform devices.GAAP EPS of $0.58, non-GAAP EPS of $0.62.Revenue of $35.0 million, an increase of 53% year-over-year.Summary of Second Quarter and Recent Highlights (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 second quarter ended Maand provided its financial outlook for its fiscal 2021.
0 Comments
Leave a Reply. |